靶向TIM-3阻止肺癌前期进展。

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-07-16 DOI:10.1016/j.trecan.2025.07.001

Kostas A Papavassiliou, Alice G Vassiliou, Athanasios G Papavassiliou

{"title":"靶向TIM-3阻止肺癌前期进展。","authors":"Kostas A Papavassiliou, Alice G Vassiliou, Athanasios G Papavassiliou","doi":"10.1016/j.trecan.2025.07.001","DOIUrl":null,"url":null,"abstract":"Little is known about lung precancer progression. Recently, Zhu et al. explored the early immunologic landscape of lung adenocarcinoma (LUAD) precursors and identified T cell immunoglobulin and mucin domain 3 (TIM-3) as a putative immune checkpoint target for precancer interception. TIM-3 blockade in mice harboring premalignant lesions delayed progression to invasive adenocarcinoma, suggesting potential clinical utility in high-risk individuals detected through screening.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":17.5000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting TIM-3 to halt lung precancer progression.\",\"authors\":\"Kostas A Papavassiliou, Alice G Vassiliou, Athanasios G Papavassiliou\",\"doi\":\"10.1016/j.trecan.2025.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Little is known about lung precancer progression. Recently, Zhu et al. explored the early immunologic landscape of lung adenocarcinoma (LUAD) precursors and identified T cell immunoglobulin and mucin domain 3 (TIM-3) as a putative immune checkpoint target for precancer interception. TIM-3 blockade in mice harboring premalignant lesions delayed progression to invasive adenocarcinoma, suggesting potential clinical utility in high-risk individuals detected through screening.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":17.5000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2025.07.001\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2025.07.001","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们对肺癌前期进展知之甚少。最近，Zhu等人探索了肺腺癌（LUAD）前体的早期免疫景观，并确定T细胞免疫球蛋白和粘蛋白结构域3 （TIM-3）是推测的癌前阻断的免疫检查点靶点。TIM-3阻断在患有癌前病变的小鼠中延缓了向侵袭性腺癌的进展，这表明通过筛查检测到的高风险个体具有潜在的临床应用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeting TIM-3 to halt lung precancer progression.

Little is known about lung precancer progression. Recently, Zhu et al. explored the early immunologic landscape of lung adenocarcinoma (LUAD) precursors and identified T cell immunoglobulin and mucin domain 3 (TIM-3) as a putative immune checkpoint target for precancer interception. TIM-3 blockade in mice harboring premalignant lesions delayed progression to invasive adenocarcinoma, suggesting potential clinical utility in high-risk individuals detected through screening.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.